Mergers & acquisitions
Eli Lilly and Company announced it was buying Loxo Oncology for $235 per share in cash, which comes to about $8 billion. The acquisition adds a lot of weight to Lilly’s oncology efforts.
- Company’s first foothold in the U.S.
Over the past decade, BMS has been no stranger to flexing its M&A muscle. The company made numerous focused-acquisitions that have positioned itself as a leader in oncology. BMS CEO Giovanni Caforio noted that the massive deal for Celgene is another piece to that puzzle.
Bristol-Myers Squibb will acquire Celgene Corporation to create a pharma giant with a significant pipeline focused on oncology, inflammatory and immunologic diseases, and cardiovascular disease.
Ohr Pharmaceutical is merging with NeuBase Therapeutics to create a public company working to advance NeuBase’s peptide-nucleic acid (PNA) antisense olignonucleotide (PATrOL) tech platform.
Boston Scientific is exercising its option to buy the remaining shares of Santa Rosa, Calif.-based Millipede. The original deal was entered into in January 2018, when Boston Scientific acquired $90 million shares with the option to buy the remaining $325 million, which the company did yesterday.
Turning an existing partner into a wholly owned subsidiary, Novartis is acquiring CellforCure from biotechnology group LFB for an undisclosed figure.
Endocyte, Inc. today announced that at its Special Meeting of Stockholders held earlier today, Endocyte’s stockholders approved the adoption of the merger agreement pursuant to which Novartis AG will acquire Endocyte for $24 per share, or a total equity value of approximately $2.1 billion, in cash.
Under the terms of the agreement, Pfizer will combine its consumer healthcare business with GSK’s existing consumer healthcare business. The combined global sales were about $12.7 billion last year. Closing is expected in the second half of 2019, dependent on GSK’s shareholder approval and regulatory approvals.
Rentschler Biopharma SE announced today that the Company has signed an agreement to purchase a manufacturing facility from an affiliate Shire plc in Milford near Boston, MA, USA.
PRESS RELEASES